D Wave Quantum Inc vs Twist Bioscience Corp — how do they compare? D Wave Quantum Inc trades at $17.18 (market cap $6.58B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| QBTS | TWST | |
|---|---|---|
Market Cap | $6.58B | $8.42B |
Sector | Technology | Health |
52-Week High | $44.78 | $153.10 |
52-Week Low | $12.98 | $24.16 |
Enterprise Value | $6.08B | $8.35B |
Signals from Pluang's Aura AI — not financial advice
QBTS trades at $17.67, up 6.57% in the last session, but remains down 33% year-to-date. The stock shows a bearish technical trend with key support at $17 and resistance at $18. Fundamentally, the company reported a net loss of $355.06 million on $24.59 million in revenue for 2025, with a negative net income margin of -2,001.59% in 2026. Recent positive news includes a $100 million funding agreement with the U.S. Department of Commerce under the CHIPS Act, announced on September 8, 2026.
Despite unanimous analyst buy ratings and a $37.00 consensus price target, significant execution risks persist. High cash burn, negative profitability, and ongoing SEC investigations pose challenges. The stock's upside depends on successful commercialization of quantum technology and effective use of government funding, but near-term volatility is expected amid sector-wide pressures and macroeconomic uncertainty.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Trailing returns across standard periods
Latest headlines on both assets
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →